42 related articles for article (PubMed ID: 11175307)
21. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
Blau N; Erlandsen H
Mol Genet Metab; 2004 Jun; 82(2):101-11. PubMed ID: 15171997
[TBL] [Abstract][Full Text] [Related]
22. Phenylalanine hydroxylase: function, structure, and regulation.
Flydal MI; Martinez A
IUBMB Life; 2013 Apr; 65(4):341-9. PubMed ID: 23457044
[TBL] [Abstract][Full Text] [Related]
23. The PAH gene, phenylketonuria, and a paradigm shift.
Scriver CR
Hum Mutat; 2007 Sep; 28(9):831-45. PubMed ID: 17443661
[TBL] [Abstract][Full Text] [Related]
24. Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients.
Pérez B; Desviat LR; Gómez-Puertas P; Martínez A; Stevens RC; Ugarte M
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S11-6. PubMed ID: 16091306
[TBL] [Abstract][Full Text] [Related]
25. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells.
Shi W; Meininger CJ; Haynes TE; Hatakeyama K; Wu G
Cell Biochem Biophys; 2004; 41(3):415-34. PubMed ID: 15509890
[TBL] [Abstract][Full Text] [Related]
26. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.
Burnett JR
IDrugs; 2007 Nov; 10(11):805-13. PubMed ID: 17968763
[TBL] [Abstract][Full Text] [Related]
27. Structural studies on phenylalanine hydroxylase and implications toward understanding and treating phenylketonuria.
Erlandsen H; Patch MG; Gamez A; Straub M; Stevens RC
Pediatrics; 2003 Dec; 112(6 Pt 2):1557-65. PubMed ID: 14654665
[TBL] [Abstract][Full Text] [Related]
28. How PAH gene mutations cause hyper-phenylalaninemia and why mechanism matters: insights from in vitro expression.
Waters PJ
Hum Mutat; 2003 Apr; 21(4):357-69. PubMed ID: 12655545
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy for phenylketonuria.
Eisensmith RC; Woo SL
Acta Paediatr Suppl; 1994 Dec; 407():124-9. PubMed ID: 7766948
[TBL] [Abstract][Full Text] [Related]
30. Phenylketonuria: epitome of human biochemical genetics (first of two parts).
Scriver CR; Clow CL
N Engl J Med; 1980 Dec; 303(23):1336-42. PubMed ID: 7001231
[No Abstract] [Full Text] [Related]
31. Gene therapy for phenylketonuria.
Eisensmith RC; Woo SL
Eur J Pediatr; 1996 Jul; 155 Suppl 1():S16-9. PubMed ID: 8828602
[TBL] [Abstract][Full Text] [Related]
32. [Disorders of tetrahydrobiopterin homeostasis].
Shintaku H; Asada M; Isshiki G; Sawada Y
Ryoikibetsu Shokogun Shirizu; 1998; (18 Pt 1):125-9. PubMed ID: 9590005
[No Abstract] [Full Text] [Related]
33. State-of-the-art 2003 on PKU gene therapy.
Ding Z; Harding CO; Thöny B
Mol Genet Metab; 2004 Jan; 81(1):3-8. PubMed ID: 14728985
[TBL] [Abstract][Full Text] [Related]
34. Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle.
Thöny B
J Inherit Metab Dis; 2010 Dec; 33(6):677-80. PubMed ID: 20151201
[TBL] [Abstract][Full Text] [Related]
35. Molecular basis of 5-hydroxytryptophan synthesis in Saccharomyces cerevisiae.
Zhang J; Wu C; Sheng J; Feng X
Mol Biosyst; 2016 Apr; 12(5):1432-5. PubMed ID: 27008988
[TBL] [Abstract][Full Text] [Related]
36. Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes.
Christensen R; Kolvraa S; Blaese RM; Jensen TG
Gene Ther; 2000 Dec; 7(23):1971-8. PubMed ID: 11175307
[TBL] [Abstract][Full Text] [Related]
37. Tetrahydrobiopterin: biochemistry and pathophysiology.
Werner ER; Blau N; Thöny B
Biochem J; 2011 Sep; 438(3):397-414. PubMed ID: 21867484
[TBL] [Abstract][Full Text] [Related]
38. Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria.
Michals-Matalon K
Expert Opin Investig Drugs; 2008 Feb; 17(2):245-51. PubMed ID: 18230057
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
